Publication | Open Access

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

Drug SafetyDisproportionality AnalysisImmunotoxicologyAdverse EventMedicineImmune Checkpoint InhibitorsImmunologyImmune Checkpoint InhibitorImmunotherapyOncologyCancer ResearchAdverse Drug Reaction